Revamped Manufacturing Process Yields Fast-Track Ryplazim Approval Three Years Later
Executive Summary
Plasminogen therapy for unmet need licensed after Prometic took the time to develop a manufacturing process it could validate.
You may also be interested in...
Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
US Senate Measure Highlights ‘Warm-Base’ Manufacturing Capacity For Next Pandemic Response
Committee's bipartisan discussion draft for legislation outlines lessons learned from COVID-19 pandemic response, including need for greater manufacturing facility readiness. Meanwhile, congressional oversight agency calls for “transformation” of response efforts.
Consortium Costs Debated As BARDA, Industry Discuss Plans For Next Pandemic Response
BARDA’s consortium approach scrutinized as industry recovers from US Defense Production Act rated orders. Questions of sustainment fees, interruptible commercial activities explored during BioMaC Industry Day call as agency emphasizes need for proven capacity.